Introduction: non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the developed world. Currently, there is no approved pharmacological therapy except for lifestyle intervention. Therefore, there is a need to increase the knowledge of preclinical models in order to boost novel discoveries that could lead to a better therapeutic management. Material and methods: this study characterized the effects of two different diets, a long-term high-fat high-fructose diet (HF-HFD) and a choline-deficient, methionine supplemented high-fat diet (CDA-HFD) in C57BL/6J mice for 52 weeks or 16 weeks, respectively. Body weight, lipid and hepatic profile were analyzed and liver histology was subsequently evaluated. Results: HF-HFD ...
<div><p>Background and aims</p><p>Non-alcoholic steatohepatitis (NASH), the potentially progressive ...
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which occurs in the ...
A variety of dietary nonalcoholic steatohepatitis (NASH) mouse models are available, and choosing th...
non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the developed worl...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Background and aims Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonalc...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The article is cop...
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which are usuall...
International audienceBACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially pro...
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and...
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonal...
<div><p>Background and aims</p><p>Non-alcoholic steatohepatitis (NASH), the potentially progressive ...
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which occurs in the ...
A variety of dietary nonalcoholic steatohepatitis (NASH) mouse models are available, and choosing th...
non-alcoholic fatty liver disease is one of the most prevalent liver disorders in the developed worl...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Background and aims Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonalc...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
Background & AimsThe lack of a preclinical model of progressive non-alcoholic steatohepatitis (NASH)...
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western wo...
This is an author's peer-reviewed final manuscript, as accepted by the publisher. The article is cop...
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), which are usuall...
International audienceBACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially pro...
Abstract Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in the world and...
BACKGROUND AND AIMS: Non-alcoholic steatohepatitis (NASH), the potentially progressive form of nonal...
<div><p>Background and aims</p><p>Non-alcoholic steatohepatitis (NASH), the potentially progressive ...
Nonalcoholic fatty liver disease (NAFLD) is characterized by hepatic steatosis, which occurs in the ...
A variety of dietary nonalcoholic steatohepatitis (NASH) mouse models are available, and choosing th...